Abstract: The present invention relates to an aqueous composition comprising a macrolide immunosuppressant drug at a concentration of less than 2% w/v and an amphiphilic carbohydrate compound having a molecular weight in the range 1-50 kDa, for use in treatment of an eye disorder by topical application to the eye, wherein the amphiphilic carbohydrate compound is present at a concentration below 10% w/v of the composition. A preferred carbohydrate compound is quaternary ammonium palmitoyl glycol chitosan (GCPQ). Pharmaceutical compositions and methods of treatment are also provided. The treatment may be for instance dry eye syndromes (DES), vernal keratoconjunctivitis (VKC), eczema, atopic keratoconjunctivitis (AKC), Sjögren syndrome, post-operative refractive surgery, corneal transplant or contact lens intolerance.
Type:
Grant
Filed:
November 2, 2015
Date of Patent:
April 27, 2021
Assignee:
Nanomerics Ltd.
Inventors:
Ijeoma Uchegbu, Andreas Schatzlein, Lorenzo Capretto
Abstract: The present invention relates to a composition comprising a hydrophilic drug and an amphiphilic carbohydrate compound for use in therapy wherein the composition is intranasally administered to the human or animal body. The composition can be used to treat a variety of disorders, including schizophrenia, obesity, pain and sleep disorders, psychiatric diseases, neurodegenerative conditions, brain cancers and infective diseases.
Type:
Grant
Filed:
November 3, 2014
Date of Patent:
February 26, 2019
Assignee:
Nanomerics LTD
Inventors:
Ijeoma Uchegbu, Andreas Schatzlein, Lisa Godfrey, Katerina Lalatsa, Antonio Iannitelli